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Abstract We studied the mechanism by which 9,13-di-cw-
retinoic acid (9,13dcRA), a novel and endogenous stereoisomer of 
all-fca/M'-RA, induces TGF-P formation in a human liver stellate 
cell line, LI90. 9,13dcRA induced the expression of RARa and 
RARP, enhanced the production of tissue-type plasminogen 
activator (tPA), thereby, surface plasmin levels, and induced the 
activation of latent TGF-p. Similar effects were obtained with 
RARa-selective retinoid, but not with RARP- or RARY-selective 
retinoid, and the induction was inhibited by RARa-selective 
antagonist. These results suggest that 9,13dcRA up-regulates 
tPA expression, resulting in the formation of TGF-P by LI90 
cells, at least in part, via induction and activation of RARa. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Transforming growth factor-P (TGF-P) is a major cytokine 
implicated in the pathogenesis of liver fibrosis/cirrhosis [1,2] 
In addition to its fibrogenic effect, TGF-P suppresses liver 
regeneration [3] and the function of hepatocytes [4]. Since 
TGF-P is mainly expressed in hepatic stellate cells (SC) in 
the damaged liver [5,6], it would be of importance to elucidate 
the mechanism by which T G F - p is induced in SCs. T G F - p , 
composed of three subtypes (TGF-P 1, -P2 and -P3), is secreted 
in a biologically latent form that must be activated before it 
can bind to its cell surface receptor and exert biological activ-
ities [7,8]. Activation releases the 25-kDa active TGF-P mol-
ecule from latency associated peptide (LAP) and its associated 
binding protein (latent TGF-P binding protein: LTBP). Plas-
min-mediated activation is best characterized and occurs in 
several cell culture systems [8]. Activation occurs at the cell 
surface by plasmin generated from serum plasminogen by the 
action of plasminogen activator (PA) [9,10]. 
Retinoic acids (RA) are active metabolites of retinol (vita-
min A) and exert profound effects on the cell growth and 
differentiation [11]. The biological effects of R A are mediated 
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all or in part by two families of nuclear receptors, R A recep-
tors (RAR) and retinoid X receptors (RXR) [12]. The RAR 
and RXR gene family each comprises three subtypes named a, 
p and y. These nuclear receptors are ligand-dependent tran-
scription factors that bind to civ-acting D N A sequences called 
R A responsive elements (RARE) or retinoid X responsive 
elements in the promoter region of the target genes [12]. To 
recognize R A R E , R A R s usually form a heterodimer with 
R X R s [12]. It has been reported that in many cell types, 
RA enhances the production of PA [11]. In bovine endothelial 
cells, elevation of surface PA/plasmin levels by R A [13] causes 
the formation of active TGF-P , and this TGF-P subsequently 
mediates some of the R A effects on endothelial cells [14,15]. 
Taken together, these findings suggest that RAs might in-
duce the formation of TGF-P in liver SCs, resulting in the 
progression of fibrogenesis. Most recently, we have found that 
a significant amount of 9,13-di-cw-RA (9,13dcRA), a novel 
stereo-isomer of all-/ra«.v-RA, is generated in the fibrotic liver 
in rat models (M. Okuno et al., unpublished observation). In 
the present study, we have investigated the molecular mecha-
nism by which 9,13dcRA enhances tissue-type PA (tPA) ex-
pression and subsequently activates latent TGF-P in liver stel-
late cells, employing the culture of a human SC cell line, LI90 
[16], as an in vitro model system. 
2. Materials and methods 
2.1. Retinoids 
9,13dcRA was kindly supplied from Eisai Co. (Tokyo, Japan). The 
pan-RAR-selective retinoid (Ch55), the RARa-selective retinoid 
(Am580), and the RAR|3-selective antagonist (LE135) were synthe-
sized and characterized as described previously [17-21]. The RAR|3-
selective retinoid (CD2019) and RARy-selective retinoid (CD437) 
were kindly provided by Dr. S. Michel (CIRD/GALDERMA, Sophia 
Antipolis, France) [22,23]. The RARa-selective antagonist Ro41-5253 
was a generous gift from Dr. M. Klaus (F. Hoffmann-La Roche, 
Basel, Switzerland) [24]. Stock solution of retinoids was made in 
ethanol and serially diluted into culture medium to yield a final etha-
nol concentration of 0.05%. 
2.2. Cell culture 
L190 cells were maintained in DMEM (Gibco, Gaithersburg, MD) 
containing 10% FCS (Gibco). The cultures were rinsed with phos-
phate-buffered saline (PBS) and incubated in serum-free DMEM con-
taining 0.2% BSA (DMEM-BSA) with either 0.05% ethanol or 1 uM 
each retinoid for 12 h. After the incubation, the medium was col-
lected, centrifuged to remove cell debris, and used for TGF-p assays. 
For zymography conditioned medium was prepared with serum-free 
DMEM without BSA. The remaining cells were washed with PBS, 
and used for either RNA isolation or assays of cellular PA and sur-
face plasmin levels. 
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Fig. 1. Augmentation of uPA secretion from the rat primary SC cultures and tPA secretion from the cultures of human SC line, LI90 by 
9,13dcRA. Confluent rat primary SCs or LI90 cells were incubated either with vehicle (control) or with 1 uM 9,13dcRA in serum-free DMEM 
for 12 h. The conditioned medium was collected, concentrated 100-fold on Microcon concentrator (Amicon) and subjected to SDS-PAGE with 
a 10% resolving gel. The gel was washed, applied onto fibrin-agar gel containing plasminogen and incubated until uPA- or tPA-derived lysis 
bands were detected. Lane 1, control rat SCs; lane 2, 9,13dcRA-treated rat SCs; lane 3, control LI90 cells; lane 4,9,13dcRA-treated LI90 cells. 
2.3. Zymography 
Zymography was carried out as described previously [25]. 
2.4. Assay of cellular PA and cell surface plasmin 
The levels of cellular PA and surface plasmin were measured using 
the chromogenic substrate S-2403, as described previously [25]. Pro-
tein concentration was measured by BCA (Pierce, Rockford, IL) assay 
using BSA as the standard. 
2.5. Assay of TGF-$ 
Active TGF-P was assayed by the inhibition of [3H]thymidine in-
corporation by CCL-64 mink lung epithelial cells as described previ-
ously [14]. 
2.6. Northern blot analysis 
Total RNA was extracted from LI90 cells using the acid guanidi-
nium thiocyanate-phenol-chloroform extraction method [26]. North-
ern blotting was performed as described previously [14]. The mem-
branes were hybridized with cDNA probes for either RARoc, -(5 or -y 
(all gifts from Dr. P. Chambon, INSERM, Universite Louis Pasteur, 
Strasbourg, France), tPA (ATCC), and TGF-P 1, -P2 or -p3 (all gifts 
from Dr. H.L. Moses, Vanderbilt University, Nashvill, TN), or glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH). Autoradiography 
was performed using a Fujix BAS 2000 Bio-imaging analyzer (Fuji 
Photo-Film, Tokyo, Japan). 
2.7. Statistics 
Each value in figures represents the average ±S.D. («=3). Unless 
noted, each similar experiment was repeated three times, representa-
tive results being shown. Significance was determined by Dunnett's t 
test. 
3. Results and discussion 
To see the effect of 9,13dcRA on the production of P A by 
hepatic SCs, we first compared the amount of PA present in 
the culture medium derived from two different kinds of hep-
atic SCs, between untreated cells and 9,13dcRA-treated cells 
(Fig. 1). Ra t primary SCs produced and secreted predomi-
nantly urokinase-type PA (uPA) (lane 1), whereas human 
SC cell line, LI90 cells, produced and secreted tPA as a dom-
inant species (lane 3). 9,13dcRA enhanced both uPA levels in 
rat pr imary SCs and tPA levels in human LI90 cells (lanes 2 
and 4, respectively). uPA has a highly strict species specificity 




















Fig. 2. Enhancement of LI90 cell PA/plasmin and TGF-P levels by 
9,13dcRA. A: After treatment of LI90 cells with 1 |xM 9,13dcRA 
for 12 h in DMEM-BSA, either cellular PA (open column) or sur-
face plasmin (slashed column) was recovered from the cultures and 
both activity levels were determined. B: The culture medium was 
collected and the levels of active TGF-p in the medium were meas-
ured as described in Section 2. Sample 1, control cells; sample 2, 
9,13dcRA-treated cells; sample 3, 9,13dcRA-treated cells in the pres-
ence of 50 u,g/ml aprotinin. *P<0.01. 










Fig. 3. Changes in the mRNA levels of RARa, -P, -y, tPA and 
TGF-pi, -p2, -p3 following the exposure of LI90 cells to 9,13dcRA. 
Confluent LI90 cell cultures were incubated either with vehicle (con-
trol; lane 1) or with 1 uM 9,13dcRA (lane 2) in DMEM-BSA for 
12 h. Total RNA was isolated from each cell sample, fractionated 
through 1% agarose-formaldehyde gels, transferred to nylon mem-
branes and hybridized with 3 P-labeled probe for RARa, -p, -y, 
tPA, TGF-pi, -P2, -P3 or GAPDH. The radioactivity of each band 
was detected on an imaging analyzer. 
different species. In contrast, tPA does not have such a species 
specificity. Because we could not obtain a probe for rat uPA, 
we decided to analyze the mechanism of 9,13dcRA-induced 
tPA expression and potential formation of TGF-P by LI90 
cells. As seen in Fig. 2, 9,13dcRA enhanced both cellular 
PA/plasmin (panel A) and TGF-P (panel B) levels in LI90 
cell cultures, and the induction of TGF-p was suggested to 
be dependent upon plasmin since an inhibitor of plasmin, 
aprotinin, alleviated 9,13dcRA-induced formation of TGF-P 
(panel B, lane 3), as in the case in endothelial cells [14]. This 
suggests that 9,13dcRA-treatment elaborated proteolytic acti-
vation of latent TGF-P in human SCs via up-regulation of 
tPA production. Because we treated LI90 cells in the serum-
free medium after rinsing the cultures with PBS, the source of 
surface plasmin is thought to be serum plasminogen bound to 
the cell surface during subculture [10]. Fig. 3 shows the result 
of changes induced in the mRNA levels of several related 
genes following the exposure of LI90 cells to 9,13dcRA. Un-
treated LI90 cells expressed nominal levels of RARP and 
RARy, but very low level of RARa. Upon treatment with 
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Fig. 4. Enhancement of cellular PA levels and induction of TGF-P formation by RARa-selective retinoid in LI90 cell cultures. After confluent 
LI90 cell cultures were incubated in DMEM-BSA for 12 h with various concentrations of 9,13dcRA or each subtype-specific retinoid, cellular 
PA activities (panels a-e) and active TGF-p levels in the medium (panels f-j) were measured as before. 
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taneously, suggesting the possible involvement of RARcx in 
the up-regulation of tPA expression. The expression of 
RARp was also enhanced by 9,13dcRA, but the expression 
of RARy was minimally affected. TGF-|32 and -p3 expressions 
were also increased by 9,13dcRA treatment, supporting the 
potential linkage between the enhanced tPA production and 
the induction of TGF-P in LI90 cells. 
Next, in order to test whether RARoc played an important 
role in 9,13dcRA-induced tPA expression and subsequent 
TGF-P formation by LI90 cells, we examined the effects of 
RAR-subtype specific agonists as well as antagonists. Fig. 4 
shows the result of agonists. LI90 cells were treated with var-
ious concentrations of 9,13dcRA or each RAR subtype-selec-
tive retinoid, and both cellular PA activity and active TGF-P 
levels in the medium were measured. Among retinoids tested, 
9,13dcRA, pan-RAR-selective Ch55 and RARa-selective 
Am580 enhanced both PA (panels a-c, respectively) and 
TGF-p (panels f-h, respectively) levels. We cannot explain 
why, roughly estimated, about 10 times higher concentrations 
of these retinoids were required for induction of TGF-P com-
pared with those required for enhancement of PA levels. In 
contrast, no induction was observed in both PA and TGF-P 
levels with RARP-selective retinoid (CD2019; panels d and i) 
or RARy-selective retinoid (CD437; panels e and j). These 
results suggest that activation of RARa may mediate 
9,13dcRA-induced tPA production and thus TGF-P forma-
tion. This was confirmed by testing the effect of subtype spe-
cific antagonist (Fig. 5). Both 9,13dcRA- and Ch55-induced 
up-regulations were blocked significantly by the co-addition 








Fig. 5. Effect of subtype-selective retinoid antagonists on the induc-
tion by 9,13dcRA of cellular PA and active TGF-P in LI90 cells. 
Confluent LI90 cell cultures were incubated in DMEM-BSA for 12 
h with vehicle (none; sample 1), 0.01 uM 9,13dcRA (sample 2) or 
the same concentration of Ch55 (sample 3), in the absence (open 
columns) and presence of 1 uM RARa-selective antagonist, Ro41-
5253 (closed columns), or RARP-selective antagonist, LEI 35 
(slashed columns). Cellular PA activities (panel A) and active TGF-
P levels in the medium (panel B) were measured as before. 
*P<0.01. 
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Fig. 6. Effects of RARa agonists and TGF-p on the mRNA levels 
of RARa and tPA in LI90 cells. After confluent LI90 cell cultures 
were incubated in DMEM-BSA for 12 h either with (A) vehicle 
(control; lane 1), 1 uM Ch55 (lane 2) or the same concentration of 
Am580 (lane 3), or (B) 1 ng/ml each of TGF-p subtypes (lanes 2-4), 
the levels of RARa and tPA mRNAs were determined by Northern 
blotting as before. Each similar experiment was repeated twice and 
the representative results are shown. 
RARP-selective antagonist, LE135. The PA and TGF-P levels 
were decreased by approximately 60~70% with Ro41-5253 
and by approximately 25~30% with LEI35. It is reported 
that al\-trans-RA up-regulates tPA expression through the 
interaction of RAR with RARE locating at 7 kb up-stream 
in the tPA promoter [27]. Together with the present results, it 
is suggested that 9,13dcRA may enhance tPA production and 
thereby induce the activation of latent TGF-P in LI90 cells, at 
least in part ( ~ 60%) through the induction and activation of 
RARa as the first step, and, therefore, both Ch55 and Am580 
should also induce the expression of the RARa gene. This was 
confirmed by Northern blotting for RARa mRNA in cultures 
of either Ch55- or Am580-treated LI90 cells. As seen in Fig. 6, 
panel A, both agonists induced the expression of RARa 
mRNA and tPA mRNA. The induction by Am580 implied 
that untreated LI90 cells expressed as small amount of RARa 
as was not fully detectable by northern blotting. The result in 
Fig. 5 also suggests that 30~40% of the induction by 
9,13dcRA was independent upon RARa. It is reported that 
RARa is expressed in both quiescent and transformed SCs in 
vivo, whereas RARp expression is down-regulated during the 
transformation in the cultures and in the fibrotic liver [28]. 
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Taken together with the findings that both RAR(3- and 
RARy-selective retinoids failed to induce tPA and TGF-P in 
SCs and that RARP-selective antagonist did not significantly 
block 9,13dcRA-induced up-regulation, it is suggested that 
RAR(3 and R A R y seemed to have relatively less effects on 
tPA induction and subsequent TGF-P formation. We need 
to examine the effect of a RARy-selective antagonist, if we 
could obtain it. Finally, in order to see whether the effects 
of 9,13dcRA on R A R a and tPA were partly mediated by 
increased TGF-P or not, RARoc and tPA m R N A expressions 
were determined following the exposure of LI90 cell cultures 
to active TGF-P 1, -p2, and -P3 for 12 h. The results are shown 
in Fig. 6, panel B. Any subtypes of TGF-Ps did not induce 
these genes, suggesting that the induction was not mediated 
by resultant T G F - p . 
The present study suggests that 9,13dcRA, a novel endog-
enous R A discovered in the fibrotic liver, may provoke in 
human SCs the enhancement of tPA and thus surface plasmin 
levels, resulting in the formation of TGF-P , and that R A R a 
may play an important role in this phenomenon. We are now 
examining if TGF-P , generated upon stimulation with 
9,13dcRA, promotes fibrogenesis, i.e. stimulation of collagen 
production. Our study might give a clue to a therapy against 
liver fibrosis, in which T G F - p plays important roles. If the 
production and activation of latent TGF-P are regulated by 
endogenous R A mainly through R A R a , the inhibition of the 
transcriptional activation via R A R a might be a strategy for 
the therapy of the disease. The use of a retinoid antagonist for 
the future therapy is now under investigation in our labora-
tory. 
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